22% Revenue Increase Year-to-Date
Update on Announced Agreement to Combine Business with Curetis
Conference call to be held at 4:30 p.m. Eastern Time today
GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. OPGN today reported financial and operating results for the three and nine months ended September 30, 2019 and provided a business update. Total nine-month revenue was $2.7 million compared with $2.2 million in 2018, a 22.4% increase. Total revenue for the third quarter of 2019 was $648 thousand, compared with $552 thousand for the third quarter of 2018, a 17.4% increase. Recent business highlights include:
- OpGen and Curetis N.V. entered into the Implementation Agreement to combine the businesses of OpGen and Curetis GmbH that will lead to, when closed, a commercial-stage, transatlantic diagnostics company focused on data-driven solutions for molecular microbiology;
- Ongoing activities to support the 510(k) pre-market notification to the U.S. Food and Drug Administration ("FDA") for clearance of the Acuitas® AMR Gene Panel test for the detection of antimicrobial resistance genes in bacterial isolates filed in May 2019;
- Initiation during November of clinical trials to support De Novo submission for our lead rapid molecular diagnostic test, the Acuitas AMR Gene Panel Urine;
- Achievement of planned program milestones under the New York State Infectious Disease Digital Health Initiative demonstration project;
- The allowance by the U.S. Patent and Trademark Office (USPTO) for a key OpGen patent covering the Acuitas Lighthouse® Profiling technology used in the Company's software for tracking AMR pathogens;
- The presentation of preliminary Acuitas® AMR Gene Panel data for detecting urinary tract infections (UTI) at IDWeek 2019. The data demonstrate the concordance of Acuitas AMR Gene Panel results with conventional urine culture results and prediction of antimicrobial resistance using the Acuitas® Lighthouse Software;
- Completion of a public offering with gross proceeds of $9.4 million. The Company intends to use a portion of the proceeds to complete the business combination with Curetis GmbH along with other planned business activities.
Evan Jones, Chairman and CEO of OpGen, stated, "The third quarter of 2019 saw a number of highlights for OpGen, most notably the transformative announcement of the planned business combination with Curetis. We believe combining the two companies will be a win for shareholders of both companies, with an expanded and proprietary product portfolio and a solid growth profile."
Mr. Jones continued, "OpGen's business had continued success during the third quarter with the achievement of key business milestones and significant progress towards gaining the first FDA clearance for our Acuitas products. We are encouraged by the positive preliminary data presented at IDWeek 2019 and the recent favorable actions by the USPTO."
"We look forward to the completion of the business combination with Curetis, expected in early 2020. The outlook for OpGen's products continues to improve and we look forward to further strengthening of our combined businesses through the planned business combination," concluded Mr. Jones.
Third Quarter and Nine Month 2019 Financial Results
- Total revenue for the third quarter of 2019 was $648 thousand, compared with $552 thousand in the third quarter of 2018. Total revenue for the nine months ended September 30, 2019 was $2.7 million, compared to $2.2 million for the nine months ended September 30, 2018;
- Operating expenses for the third quarter of 2019 were $4.1 million, compared with $3.8 million in the third quarter of 2018. Total operating expenses for the nine months ended September 30, 2019 were $12.4 million, compared to $11.7 million for the nine months ended September 30, 2018;
- The net loss for the third quarter of 2019 was $3.5 million or $3.95 per share, compared with $3.3 million or $10.67 per share in the third quarter of 2018. The net loss for the nine months ended September 30, 2019 was $9.9 million or $13.32 per share, compared to $9.6 million or $36.09 per share for the period ending September 30, 2018.
Business and Operations Outlook
We anticipate achieving the following:
- Complete planned business combination with Curetis in the first quarter of 2020;
- Obtain FDA clearance to market the Acuitas AMR Gene Panel for use with bacterial Isolates;
- Complete clinical studies and file De Novo submissions with the FDA for the Acuitas AMR Gene Panel Urine and the Acuitas Lighthouse Software for rapid testing of urine specimens and prediction of antibiotic resistance to front-line antibiotics; and
- Complete data collection phase for New York State Infectious Disease Digital Health Initiative demonstration project.
Conference Call Information
OpGen's management will host a conference call today, November 6 at 4:30 p.m. ET to discuss third quarter 2019 financial results and other business activities, as well as answer questions. Dial-in information is below:
Dial-in Information
U.S. Dial-in Number: (844) 420-8185
International Dial-in Number: +1 (216) 562-0481
Webcast: https://edge.media-server.com/mmc/p/p64ma2dv
Conference ID: 2899666
Following the conclusion of the conference call, a replay will be available through November 13, 2019. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company's website at ir.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company's website for 90 days. Replay access information is below:
Replay Information
U.S. Dial-in Number: (855) 859-2056
International Dial-in Number: +1 (404) 537-3406
Conference ID: 2899666
About OpGen
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. We are developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.
Our molecular diagnostics and informatics products, product candidates and services combine our Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with our proprietary, curated MDRO knowledgebase. We are working to deliver our products and services, some in development, to a global network of customers and partners. The Acuitas AMR Gene Panel (RUO) is intended for Research Use Only and is not for use in diagnostic procedures. The Acuitas Lighthouse Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures. For more information, please visit www.opgen.com.
OpGen, Acuitas, and Acuitas Lighthouse are registered trademarks of OpGen, Inc.
Forward-Looking Statements
This press release includes statements relating to the completion of the business combination with Curetis N.V., pursuit of FDA clearance for the Acuitas AMR Gene Panel for use with bacterial Isolates, the use of proceeds from the October 2019 public offering and the activities related to the Company's products and services. These statements and other statements regarding OpGen's future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the fact that we have broad discretion as to the use of proceeds from the October 2019 public offering and that we may not use the proceeds effectively; risks and uncertainties associated with market conditions, OpGen's ability to successfully and timely seek approval of, and obtain approval of its stockholders for the business combination with Curetis N.V., satisfy the closing conditions under the Implementation Agreement, successfully combine the businesses of OpGen and Curetis GmbH, comply with the complexities of a global business, achieve the synergies we expect, successfully implement the combined company's strategic and business goals and objectives, advance our current and planned 510(k) clearance submissions with the FDA, and continue our activities under the New York State Infectious Disease Digital Health Initiative. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen Contact:
Michael Farmer
Vice President, Marketing
(240) 813-1284
mfarmer@opgen.com
Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com
Investor Contact:
Joe Green
Edison Group
jgreen@edisongroup.com
| OpGen, Inc. | ||||||||||
| Condensed Consolidated Balance Sheets | ||||||||||
| September 30, 2019 | December 31, 2018 | |||||||||
| Assets | (Unaudited) | |||||||||
| Current assets | ||||||||||
| Cash and cash equivalents | $ | 626,420 | $ | 4,572,487 | ||||||
| Accounts receivable, net | 377,284 | 373,858 | ||||||||
| Inventory, net | 468,374 | 543,747 | ||||||||
| Prepaid expenses and other current assets | 533,411 | 292,918 | ||||||||
| Total current assets | 2,005,489 | 5,783,010 | ||||||||
| Property and equipment, net | 201,762 | 1,221,827 | ||||||||
| Finance lease right-of-use assets, net | 1,096,472 | — | ||||||||
| Operating lease right-of-use assets | 1,214,482 | — | ||||||||
| Goodwill | 600,814 | 600,814 | ||||||||
| Intangible assets, net | 884,504 | 1,085,366 | ||||||||
| Other noncurrent assets | 426,629 | 259,346 | ||||||||
| Total assets | $ | 6,430,152 | $ | 8,950,363 | ||||||
| Liabilities and Stockholders' Equity (Deficit) | ||||||||||
| Current liabilities | ||||||||||
| Accounts payable | $ | 1,872,762 | $ | 1,623,751 | ||||||
| Accrued compensation and benefits | 1,387,498 | 1,041,573 | ||||||||
| Accrued liabilities | 1,040,562 | 902,019 | ||||||||
| Deferred revenue | 9,808 | 15,824 | ||||||||
| Short-term notes payable | 508,292 | 398,595 | ||||||||
| Short-term finance lease liabilities | 627,620 | 399,345 | ||||||||
| Short-term operating lease liabilities | 987,833 | — | ||||||||
| Total current liabilities | 6,434,375 | 4,381,107 | ||||||||
| Deferred rent | — | 162,919 | ||||||||
| Note payable | 328,843 | 660,340 | ||||||||
| Warrant liability | — | 67 | ||||||||
| Long-term finance lease liabilities | 411,103 | 437,189 | ||||||||
| Long-term operating lease liabilities | 812,801 | — | ||||||||
| Total liabilities | 7,987,122 | 5,641,622 | ||||||||
| Commitments | ||||||||||
| Stockholders' equity (deficit) | ||||||||||
| Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at September 30, 2019 and December 31, 2018, respectively | — | — | ||||||||
| Common stock, $0.01 par value; 50,000,000 shares authorized; 882,268 and 432,286 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively | 8,823 | 4,323 | ||||||||
| Additional paid-in capital | 170,449,216 | 165,396,036 | ||||||||
| Accumulated deficit | (172,007,090 | ) | (162,078,525 | ) | ||||||
| Accumulated other comprehensive loss | (7,919 | ) | (13,093 | ) | ||||||
| Total stockholders' equity (deficit) | (1,556,970 | ) | 3,308,741 | |||||||
| Total liabilities and stockholders' equity (deficit) | $ | 6,430,152 | $ | 8,950,363 | ||||||
| OpGen, Inc. | ||||||||||||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||||
| (unaudited) | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||||
| Revenue | ||||||||||||||||||
| Product sales | $ | 573,035 | $ | 539,856 | $ | 1,597,505 | $ | 1,805,877 | ||||||||||
| Laboratory services | 185 | 12,365 | 5,435 | 22,155 | ||||||||||||||
| Collaboration revenue | 75,000 | — | 1,075,000 | 359,316 | ||||||||||||||
| Total revenue | 648,220 | 552,221 | 2,677,940 | 2,187,348 | ||||||||||||||
| Operating expenses | ||||||||||||||||||
| Cost of products sold | 262,373 | 292,984 | 681,568 | 939,479 | ||||||||||||||
| Cost of services | 196,184 | 98,189 | 592,647 | 446,144 | ||||||||||||||
| Research and development | 1,139,369 | 1,286,300 | 4,069,335 | 3,821,117 | ||||||||||||||
| General and administrative | 1,560,706 | 1,743,636 | 4,901,136 | 5,365,221 | ||||||||||||||
| Sales and marketing | 376,955 | 361,310 | 1,142,755 | 1,117,380 | ||||||||||||||
| Transaction costs | 538,061 | — | 538,061 | — | ||||||||||||||
| Impairment of right-of-use asset | — | — | 520,759 | — | ||||||||||||||
| Total operating expenses | 4,073,648 | 3,782,419 | 12,446,261 | 11,689,341 | ||||||||||||||
| Operating loss | (3,425,428 | ) | (3,230,198 | ) | (9,768,321 | ) | (9,501,993 | ) | ||||||||||
| Other (expense) income | ||||||||||||||||||
| Other income (expense) | 1,043 | (93 | ) | (8,213 | ) | 5,210 | ||||||||||||
| Interest expense | (49,099 | ) | (28,074 | ) | (142,672 | ) | (140,453 | ) | ||||||||||
| Foreign currency transaction gains (losses) | (8,954 | ) | 3,025 | (9,426 | ) | (6,556 | ) | |||||||||||
| Change in fair value of derivative financial instruments | — | (85 | ) | 67 | 8,070 | |||||||||||||
| Total other expense | (57,010 | ) | (25,227 | ) | (160,244 | ) | (133,729 | ) | ||||||||||
| Loss before income taxes | (3,482,438 | ) | (3,255,425 | ) | (9,928,565 | ) | (9,635,722 | ) | ||||||||||
| Provision for income taxes | — | — | — | — | ||||||||||||||
| Net loss | (3,482,438 | ) | (3,255,425 | ) | (9,928,565 | ) | (9,635,722 | ) | ||||||||||
| Net loss available to common stockholders | $ | (3,482,438 | ) | $ | (3,255,425 | ) | $ | (9,928,565 | ) | $ | (9,635,722 | ) | ||||||
| Net loss per common share - basic and diluted | $ | (3.95 | ) | $ | (10.67 | ) | $ | (13.32 | ) | $ | (36.09 | ) | ||||||
| Weighted average shares outstanding - basic and diluted | 882,280 | 305,187 | 745,471 | 266,997 | ||||||||||||||
| Net loss | $ | (3,482,438 | ) | $ | (3,255,425 | ) | $ | (9,928,565 | ) | $ | (9,635,722 | ) | ||||||
| Other comprehensive gain foreign currency translations | 7,298 | 1,528 | 5,174 | 7,062 | ||||||||||||||
| Comprehensive loss | $ | (3,475,140 | ) | $ | (3,253,897 | ) | $ | (9,923,391 | ) | $ | (9,628,660 | ) | ||||||
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
